January 2, 2018 / 12:09 PM / 5 months ago

BRIEF-Merck’s Keytruda Approved In Japan For Use In The Treatment Of Patients With Urothelial Carcinoma

Jan 2 (Reuters) - Merck & Co Inc:

* MERCK’S KEYTRUDA® (PEMBROLIZUMAB) APPROVED IN JAPAN FOR USE IN THE TREATMENT OF PATIENTS WITH UROTHELIAL CARCINOMA THAT IS UNRESECTABLE WITH RADICAL SURGERY WHO HAVE PROGRESSED FOLLOWING CANCER CHEMOTHERAPY

* MERCK & CO INC - WILL MARKET KEYTRUDA IN JAPAN AND WILL PROMOTE IT WITH TAIHO PHARMACEUTICAL CO LTD

* MERCK & CO INC - WITH THE APPROVAL, KEYTRUDA IS NOW INDICATED FOR USE IN FOUR TYPES OF CANCER IN JAPAN Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below